Department of Pathology, Johns Hopkins University School of Medicine, Baltimore.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
J Infect Dis. 2018 Jun 5;218(1):109-113. doi: 10.1093/infdis/jiy165.
In the United States, human papillomavirus (HPV) vaccination has been recommended for females since 2006 and males since 2011. We assessed temporal trends in HPV vaccine coverage (defined as receipt of ≥1 dose) among 9-26-year-old participants in the 2011-2016 National Health and Nutrition Examination Surveys. While coverage increased overall, from 37.7% to 45.7%, among females (adjusted prevalence difference [aPD], 7.1%; 95% confidence interval [CI], .1%-13.7%), there was no change among female adolescents aged 9-17 years. For males, coverage increased overall, from 7.8% to 27.4% (aPD, 18.8%; 95% CI, 14.1%-23.5%), and among every stratum of age, race/ethnicity, health insurance status, poverty level, and immigration status (P ≤ .05). The increase in HPV vaccine coverage observed among males is encouraging, but coverage remains below national targets for both males and females.
在美国,自 2006 年以来,HPV 疫苗已被推荐用于女性,自 2011 年以来,也被推荐用于男性。我们评估了 2011 年至 2016 年全国健康和营养调查中 9-26 岁参与者 HPV 疫苗接种率(定义为至少接种 1 剂)的时间趋势。尽管女性的接种率总体上有所增加,从 37.7%增加到 45.7%(调整后患病率差异[aPD]为 7.1%;95%置信区间[CI]为.1%至 13.7%),但 9-17 岁的少女群体中没有变化。对于男性,接种率总体上有所增加,从 7.8%增加到 27.4%(aPD 为 18.8%;95%CI 为 14.1%至 23.5%),而且在所有年龄、种族/族裔、医疗保险状况、贫困水平和移民状况的阶层中(P ≤.05)都有增加。观察到男性 HPV 疫苗接种率的增加令人鼓舞,但男性和女性的接种率仍低于全国目标。